Researchers identified the inhibitor JQ1 as a potential drug to improve immune response to CAR T-cell therapies in leukaemia patients.
List view / Grid view
Chronic lymphocytic leukaemia (CLL)
A team of researchers in Spain show for the first time the complete epigenome of chronic lymphocytic leukaemia, the most common type of leukaemia.
Researchers have discovered the reason why some patients with advanced chronic lymphocytic leukaemia (CLL) don't respond to chimeric antigen receptor (CAR) T cell therapy...